Zinc-Carnosine and its application in gastritis

Zinc-carnosine is a chelate of a zinc ion plus carnosine in a 1:1 ratio. This formula has been used in Japan since 1994 to treat various gastric ailments, and has been shown to be three times more effective than using these ingredients alone and has greater ulcer-healing effects than cimetidine, a first-generation antiulcer drug with significant drug interactions.

Why Zinc? Zinc is vital for over 300 biochemical reactions in your body. It is essential for tissue repair, normal growth, and the immune system. It has been used in the treatment of various gastrointestinal diseases, including peptic ulcers.

Why Carnosine? Carnosine, present in organs such as the brain and muscles, has a slow dissociation in gastric juice. This allows the zinc-carnosine complex to bind to inflamed tissue, exerting anti-inflammatory and healing effects directly on the gastrointestinal tissue.

Practical Uses of Zinc Carnosine: In addition to healing damage to gastric tissue, zinc carnosine has shown success in improving injury to the small intestine. It may be beneficial in treating diseases such as celiac disease and irritable bowel syndrome.

Zinc Carnosine Actions: From antacid effects to cellular protection and accelerated wound healing, zinc carnosine has a wide range of applications that can help you with your gastric health and beyond.

The recommended dose is 75 mg of zinc-carnosine twice daily.

In summary, zinc-carnosine is a safe and effective option, either as a stand-alone therapy or as a complementary treatment in gastric, liver and intestinal disorders.

At Matter, we have Pepcil-GI , a Zinc-Carnosine supplement in its chelated form to ensure its absorption.

We also invite you to discover GI-Fix , an intestinal microbiota repairer with Zinc-Carnosine as one of its main active ingredients.

References:

1. Takei M. [Development of polaprezinc research].[Article in Japanese]. Yakugaku Zasshi 2012;132(3):271-277. [ Abstract or in English ]
    
2. Hayakawa A, Inoue M, Kunizaki M, et al. Clinical evaluation of Z-103 on gastric ulcer (thesis). Japan Pharmacol Ther 1992;20(1):1-18. [ Full text ]
    
3. Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastritis, Ref. 30. A multicenter double-blind dose finding study. Jpn Pharmacol Ther 1997;25(5):1403-1442. [ Full text ]
    
4. Mori K, Karino A, Murakami A, et al. Phase III clinical study of Z-103 tablet against gastric ulcers. [ Full text ]
    
5. Matsukura T, Tanaka H. Applicability of zinc complex of L-carnosine for medical use. Biochemistry (Moscow). 2000;65(7):817-823. [ Full text ]
    
6. Furuta S, Toyama S, Miwa M, et al. Residence time of polaprezinc (zinc L-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites. Jpn J Pharmacol 1995;67(4):271-278. [ Full text ]
    
7. DiSilvestro R. Polaprezinc FDA evaluation. 2002 Sect 6, Att C, Vol 98. [ Full text ]
    
8. Lee SR, Noh SJ, Pronto JR, et al. The critical roles of zinc: beyond impact on myocardial signaling. Korean J Physiol Pharmacol 2015;19(5):389-399. [ Full text ]
    
9. Skrovanek S, DiGuilio K, Bailey R, et al. Zinc and gastrointestinal disease. World J Gastrointest Pathophys 2014;5(4):496-513. [ Full text ]
    
10. Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilizes small bowel integrity and stimulates gut repair processes. Gut 2007;56(2):168-175. [ Full text ]
     
11. Watari I, Oka S, Tanaka S, et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol. 2013;13:108. [ Full text ]
     
12. Watanabe T, Ishihara M, Matsuura K, et al. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer 2010;127(8):1984-1990. [Full text ]
     
13. Hayashi H, Kobayashi R, Suzuki A, et al. Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res 2014;34(12):7271-7277. [ Full Text ]
     
14. Sakae K, Yanagisawa H. Oral treatment of pressure ulcers with polaprezinc (zinc L-carnosine complex): 8-week open-label trial. Biol Trace Elem Res 2014;158(3):280-288. [ Abstract ]
     
15. Itagaki M, Saruta M, Saijo H, et al. Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis. Scand J Gastroenterol 2014;49(2):164-172. [ Abstract ]
     
16. Sakagami M, Ikeda M, Tomita H, et al. A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study. Acta Otolaryngol 2009;129(10):1115-1120. [ Abstract ]
17. Takagi H, Nagamine T, Abe T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 2001;8(5):367-371. [ Abstract ]